Daily Intelligence Brief
Daily Docket: Snap Pulls Pennsylvania AG's Snapchat Suit Into Federal Court
We tracked 293 new filings across 23 litigations. Terrorist Attacks on September 11, 2001 Litigation (1570) led with 204 filings, with Anderson Kill PC (204) as top filer. Aqueous Film-Forming Foams Products Liability Litigation (2873) added 20 filings, led by Stag Liuzza LLC (6) and Krentsel & Guzman LLP (6) as top filers. Social Media Adolescent Addiction Personal Injury Products Liability Litigation (3047) drew 19 filings, led by Levin Papantonio (9) and Brent Coon & Associates (3) as top filers. See the full filing feed and firm-level breakdowns here.
EPA-HHS Glyphosate Partnership Resets the Evidence Calendar
EPA and HHS announced a Memorandum of Understanding on Sept. 22 to expand the scientific review supporting EPA’s ongoing glyphosate registration review. The agencies’ technical working group will examine formulation toxicology, occupational epidemiology, human exposure, dietary exposure and cancer evidence, broadening the federal record beyond EPA’s existing review process. EPA retains final authority over any registration decision and has set an updated human-health risk assessment for late 2026, followed by a public webinar expected in early 2027. For Roundup (2741), the partnership creates a new federal evidence track that both sides will scrutinize as they frame expert proof and regulatory-risk arguments.
New Paracetamol Review Enters Acetaminophen Causation Fight
A peer-reviewed umbrella review examining prenatal paracetamol exposure and autism and attention-deficit/hyperactivity disorder was published online on Sept. 23, adding a current synthesis to the scientific dispute surrounding Acetaminophen – ASD-ADHD Products Liability (3043). The publication places a newly consolidated body of epidemiological literature before lawyers assessing the strength and limits of the causation record. Plaintiffs can test the review for support across the underlying research, while defendants can probe whether its synthesis resolves the exposure, confounding and causation questions central to the claims. Its immediate consequence is evidentiary: the parties now have a fresh peer-reviewed reference point for expert preparation and challenges.
Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
